Ascofen (acetylsalicylic acid) tablets №10

active ingredients: acetylsalicylic acid, paracetamol, caffeine;

1 tablet contains: acetylsalicylic acid 200 mg, paracetamol 200 mg, caffeine 40 mg;

excipients : citric acid monohydrate, potato starch, povidone, calcium stearate.

Pills.

Basic physical and chemical properties : tablets of white color, flat-cylindrical shape, with a chamfer and risk. Marbling is allowed on the surface of the tablets.

Analgesics. Other analgesics and antipyretics. Acetylsalicylic acid, combinations without psycholeptics. ATX code N02B A51.

Ascofen (acetylsalicylic acid) has an analgesic, antipyretic and anti-inflammatory effect. The components that make up the drug enhance the effects of each other.

The antipyretic effect of acetylsalicylic acid is realized through the central nervous system by inhibiting the synthesis of PGF2 prostaglandins in the hypothalamus in response to exposure to endogenous pyrogens. The analgesic effect has both peripheral and central origin: peripheral effect – inhibition of the synthesis of prostaglandins in inflamed tissues; central effect – influence on the centers of the hypothalamus. Acetylsalicylic acid also reduces platelet aggregation.

Paracetamol has an analgesic, antipyretic and very weak anti-inflammatory effect, which is associated with its effect on the thermoregulatory center in the hypothalamus and a weak ability to inhibit the synthesis of prostaglandins in peripheral tissues.

Caffeine excites the central nervous system. It also enhances positive conditioned reflexes, stimulates motor activity, weakens the effect of sleeping pills and narcotic substances, enhances the effect of analgesics and antipyretics.

Has not been studied.

Therapy of mild or moderate pain syndrome: for headache or toothache, neuralgia, myalgia, arthralgia, for primary dysmenorrhea, and also as an antipyretic for diseases that are accompanied by fever.

• Hypersensitivity to the components of Ascofen (acetylsalicylic acid), hypersensitivity to other xanthine derivatives (theophylline, theobromine), other salicylates;
• bronchial asthma, urticaria or rhinitis caused by taking salicylates or other NSAIDs in history;
• congenital hyperbilirubinemia, severe renal failure or liver failure, Gilbert’s syndrome, congenital deficiency of glucose-6-phosphate dehydrogenase;
• blood diseases, hemophilia, hemorrhagic diathesis, hypoprothrombinemia, anemia, leukopenia, increased bleeding tendency, thrombosis, thrombophlebitis, hemorrhagic diseases;
• acute gastrointestinal ulcers, gastrointestinal bleeding, surgical interventions accompanied by significant bleeding;
• severe cardiovascular diseases, including rhythm disturbances, paroxysmal tachycardia, severe atherosclerosis, severe coronary heart disease, severe heart failure, acute myocardial infarction, severe arterial hypertension, portal hypertension, a tendency to vasospasm;
• states of increased arousal, sleep disturbances, old age, alcoholism, glaucoma, hyperthyroidism, acute pancreatitis, prostatic hypertrophy, severe forms of diabetes mellitus.

Use simultaneously with MAO inhibitors, as well as within 2 weeks after stopping their use. Combination with methotrexate at a dose of 15 mg/week or more.

Contraindicated in patients using tricyclic antidepressants or β-blockers.